Trial Profile
Study Comparing Full-Dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Advanced breast cancer; Breast cancer; Cancer metastases
- Focus Therapeutic Use
- Sponsors Novartis
- 30 Mar 2010 Actual patient number (116) added as reported by ClinicalTrials.gov.
- 13 Sep 2005 New trial record.